Log in | Register

Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis

Mikkel Allingstrup| Jørn Wetterslev| Frederikke B. Ravn| Ann Merete Møller| Arash Afshari
Systematic Review
Volume 42, Issue 4 / April , 2016

Pages 505 - 520

Abstract

Purpose

Antithrombin III (AT III) is an anticoagulant with anti-inflammatory properties. We assessed the benefits and harms of AT III in critically ill patients.

Methods

We searched from inception to 27 August 2015 in CENTRAL, MEDLINE, EMBASE, CAB, BIOSIS and CINAHL. We included randomized controlled trials (RCTs) irrespective of publication status, date of publication, blinding status, outcomes published or language.

Results

We included 30 RCTs with a total of 3933 participants. The majority of included trials were at high risk of bias. Combining all trials, regardless of bias, showed no statistically significant effect of AT III on mortality (RR 0.95, 95 % CI 0.88–1.03, I2 = 0 %, fixed-effect model, 29 trials, 3882 participants). Among those with severe sepsis and disseminated intravascular coagulation (DIC), AT III showed no impact on mortality (RR 0.95, 95 % Cl 0.88–1.03, I2 = 0 %, fixed-effect model, 12 trials, 2858 participants). We carried out multiple subgroup and sensitivity analyses to assess the benefits and harms of AT III and to examine the impact of risk of bias. AT III significantly increased bleeding events (RR 1.58, 95 % CI 1.35–1.84, I2 = 0 %, fixed-effect model, 11 trials, 3019 participants). However, for all other outcome measures and analyses, the results did not reach statistical significance.

Conclusions

There is insufficient evidence to support AT III substitution in any category of critically ill participants including those with sepsis and DIC. AT III did not show an impact on mortality, but increased the risk of bleeding.

Keywords

References

  1. Wunsch H, Angus D, Harrison D et al (2008) Variation in critical care services across North America and Western Europe. Crit Care Med 36:2787–2793
    • View reference on publisher's website
    • View reference on PubMed
  2. Levi M, De Jonge E, Van der Poll T (2004) New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med 36:41–49
    • View reference on publisher's website
    • View reference on PubMed
  3. Mayr F, Yende S, Angus D (2014) Epidemiology of severe sepsis. Virulence 5:4–11
    • View reference on publisher's website
    • View reference on PubMed
  4. Periti P (2000) Current treatment of sepsis and endotoxaemia. Expert Opin Pharmacother 1:1203–1217
    • View reference on publisher's website
    • View reference on PubMed
  5. Polderman KH, Girbes ARJ (2004) Drug intervention trials in sepsis: divergent results. Lancet 363:1721–1723
    • View reference on publisher's website
    • View reference on PubMed
  6. Becker BF, Heindl B, Kupatt C, Zahler S (2000) Endothelial function and hemostasis. Z Kardiol 89:160–167
    • View reference on PubMed
  7. Diaz R, Moffett BS, Karabinas S et al (2015) Antithrombin concentrate use in children receiving unfractionated heparin for acute thrombosis. J Pediatr 167:645–649
    • View reference on publisher's website
    • View reference on PubMed
  8. Opal SM, Kessler CM, Roemisch J, Knaub S (2002) Antithrombin, heparin, and heparan sulfate. Crit Care Med 30:325–331
    • View reference on publisher's website
  9. Rublee D, Opal SM, Schramm W et al (2002) Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial. Crit Care 6:349–356
    • View reference on publisher's website
    • View reference on PubMed
  10. Zarychanski R, Abou-Setta AM, Kanji S et al (2015) The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med 43:511–518
    • View reference on publisher's website
    • View reference on PubMed
  11. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926
    • View reference on publisher's website
    • View reference on PubMed
  12. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535
    • View reference on publisher's website
    • View reference on PubMed
  13. Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. http://www.cochrane-handbook.org. Accessed March 2011
  14. Afshari A, Wetterslev J, Brok J, Møller A (2008) Antithrombin III for critically ill patients. Cochrane Database Syst Rev 16(3):5370
  15. The Cochrane Collaboration (2014) Review Manager (RevMan), version 5.3.5. The Nordic Cochrane Centre, Copenhagen
  16. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C (2011) User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, pp 1–115. http://www.ctu.dk/tsa/files/tsa_manual.pdf
  17. Albert J, Blomqvist H, Gardlund B et al (1992) Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiol Scand 36:745–752
    • View reference on publisher's website
    • View reference on PubMed
  18. Balk RA, Bedrosian C, McCormick L et al (1995) Prospective double blind placebo-controlled trial of ATIII substitution in sepsis. Intensive Care Med 21:17
  19. Baudo F, DeGasperi A, De Cataldo F et al (1992) Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thromb Res 68:409–416
    • View reference on publisher's website
    • View reference on PubMed
  20. Baudo F, Caimi TM, De Cataldo F et al (1998) Antithrombin III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 24:336–342
  21. Blauhut B, Kramar H, Vinazzer H, Bergmann H (1985) Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 39:81–89
    • View reference on publisher's website
    • View reference on PubMed
  22. Diaz-Cremades JM, Lorenzo R, Sánchez M et al (1994) Use of antithrombin III in critical patients. Intensive Care Med 20:577–580
  23. Eisele B, Lamy M, Thijs LG et al (1998) Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 24:663–672
  24. Fourrier F, Chopin C, Huart JJ et al (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882–888
    • View reference on publisher's website
    • View reference on PubMed
  25. Fulia F, Cordaro S, Meo P et al (2003) Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants. Biol Neonate 83:1–5
    • View reference on publisher's website
    • View reference on PubMed
  26. Gando S, Saitoh D, Ishikura H et al (2013) A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care 17:297
    • View reference on publisher's website
  27. Grenander A, Bredbacka S, Rydvall A et al (2001) Antithrombin treatment in patients with traumatic brain injury: a pilot study. J Neurosurg Anesthesiol 13:49–56
    • View reference on publisher's website
    • View reference on PubMed
  28. Haire WD, Ruby EI, Stephens LC et al (1998) A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 4:142–150
    • View reference on publisher's website
    • View reference on PubMed
  29. Harper PL, Williamson L, Park G et al (1991) A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfus Med 1:121–128
    • View reference on publisher's website
    • View reference on PubMed
  30. Inthorn D, Hoffmann JN, Hartl WH et al (1997) Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock 8:328–334
    • View reference on publisher's website
    • View reference on PubMed
  31. Kobayashi T, Terao T, Ikenoue T et al (2003) Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Semin Thromb Hemost 29:645–652
    • View reference on publisher's website
    • View reference on PubMed
  32. Langley PG, Hughes RD, Forbes A et al (1993) Controlled trial of antithrombin III supplementation in fulminant hepatic failure. J Hepatol 17:326–331
    • View reference on publisher's website
    • View reference on PubMed
  33. Lavrentieva A, Kontakiotis T, Bitzani M et al (2008) The efficacy of antithrombin administration in the acute phase of burn injury. Thromb Haemost 100:286–290
    • View reference on PubMed
  34. Maki M, Kobayashi T, Terao T et al (2000) Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. Thromb Haemost 84:583–590
    • View reference on PubMed
  35. Mitchell L, Andrew M, Hanna K et al (2003) Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 90:235–244
    • View reference on PubMed
  36. Muntean W, Rossegger H (1989) Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thromb Haemost 62:288
  37. Neporada E, Vorobyeva N, Nedashkovsky E (2008) Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatol 5:49–54
    • View reference on publisher's website
  38. Nishiyama T, Kohno Y, Koishi K (2012) Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study. Am J Emerg Med 30:1219–1223
    • View reference on publisher's website
    • View reference on PubMed
  39. Palareti G, Legnani C, Coccheri S et al (1995) Laboratory effects of antithrombin-III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support—a controlled, double-blind, randomized multicenter study. Thromb Haemost 73:1251
  40. Schmidt B, Gillie P, Mitchell L et al (1998) A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 158:470–476
    • View reference on publisher's website
    • View reference on PubMed
  41. Schorr M, Siebeck M, Zugel N et al (2000) Antithrombin III and local serum application: adjuvant therapy in peritonitis. Eur J Clin Invest 30:359–366
    • View reference on publisher's website
    • View reference on PubMed
  42. Schuster HP, Eisele B, Keinecke HO et al (1997) S-AT III study: antithrombin III in patients with sepsis. Intensive Care Med 23(Suppl 1):76
  43. Smith-Erichsen N, Aasen AO, Kongsgaard UE et al (1996) The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clin Intensive Care 7:291–296
    • View reference on publisher's website
  44. Vorobyeva N, Neporada E, Turundaevskaia O, Mel’nikova G (2007) Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziol Reanimatol 2:42–44
  45. Warren BL, Eid A, Singer P et al (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA 286:1869–1878
    • View reference on publisher's website
    • View reference on PubMed
  46. Waydhas C, Nast-Kolb D, Gippner-Steppert C et al (1998) High-dose antithrombin III treatment of severely injured patients: results of a prospective study. J Trauma 45:931–940
    • View reference on publisher's website
    • View reference on PubMed
  47. D’Angelo A, Valsecchi L (2015) High-dose antithrombin supplementation in early pre-eclampsia: a double-blind, placebo controlled study (on behalf of the AT III-EPAS study group). http://abstract.mci-group.com/cgi-bin/mc/printabs.pl?APP=ISTH2009ABS-abstract&TEMPLATE=&keyf=0771&showHide=show&client. Accessed 21 April 2015
  48. Gotzsche PC (2000) Why we need a broad perspective on meta-analysis. It may be crucially important for patients. BMJ 321:585–586
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement